- Conditions
- Obesity
- Interventions
- Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 35 Years to 60 Years
- Enrollment
- 30 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tomivosertib, Pembrolizumab, Pemetrexed
- Drug · Biological
- Lead sponsor
- Effector Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 131
- States / cities
- Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Ipilimumab, Cryoablation, Nivolumab
- Drug · Procedure
- Lead sponsor
- Kristen Ganjoo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Healthy
- Interventions
- JNJ-42847922, Rifampin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Meningitis, Cryptococcal, HIV Infections
- Interventions
- Flucytosine, Fluconazole, Amphotericin B
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 6
- States / cities
- Miami, Florida • New Orleans, Louisiana • New York, New York + 3 more
- Conditions
- Surgical Site Infection
- Interventions
- Chloraprep, 0.9% Physiological Saline, ZuraPrep without IPA
- Drug · Other
- Lead sponsor
- Zurex Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Bozeman, Montana
- Conditions
- Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab ozogamicin, Dasatinib, Dexamethasone, Methotrexate, Vincristine, Ponatinib, Purinethol (6-Mercaptopurine), Prednisone
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
- Interventions
- DS3790a, Combination drug
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Cancer
- Interventions
- Binimetinib, Palbociclib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Postoperative Pain
- Interventions
- Dexamethasone, Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Atovaquone, Sulfamethoxazole-Trimethoprim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Harbor City, California • Los Angeles, California + 15 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Lamivudine, Zidovudine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Whitehouse Station, New Jersey
- Conditions
- High-grade Extra Pulmonary Neuroendocrine Cancer
- Interventions
- All patients- TAS-102
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Disease, Hodgkin
- Interventions
- brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, bleomycin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Chapel Hill, North Carolina • Houston, Texas
- Conditions
- Drug-Resistant Epilepsy, Focal-Onset Seizures
- Interventions
- Padsevonil, Placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more
- Conditions
- Advanced Incurable Solid Malignancy
- Interventions
- Vandetanib, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Leonard Appleman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- HIV
- Interventions
- Atazanavir, Raltegravir, Ritonavir, Tenofovir/Emtricitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more
- Conditions
- Neoplasms
- Interventions
- Axitinib + Paclitaxel + Carboplatin (Cohort 1), Axitinib + Paclitaxel + Carboplatin (Cohort 2), Axitinib + Paclitaxel + Carboplatin (Cohort 3), Axitinib + Paclitaxel (Cohort 4), Axitinib + Docetaxel + Carboplatin (Cohort 4a), Axitinib + Docetaxel (Cohort 5), Axitinib + Capecitabine (Cohort 6), Axitinib + Capecitabine (Cohort 7), Axitinib + Gemcitabine + Cisplatin (Cohort 8), Axitinib + Pemetrexed + Cisplatin (Cohort 9)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 10
- States / cities
- Augusta, Georgia • Harvey, Illinois • Tinley Park, Illinois + 5 more
- Conditions
- Seasonal Allergic Conjunctivitis
- Interventions
- Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
- Interventions
- BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN
- Drug
- Lead sponsor
- Gauda, Estelle B., M.D.
- Individual
- Eligibility
- Up to 7 Days
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- HIV, Buprenorphine, Opioid Dependence
- Interventions
- Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- PrEP Adherence Monitoring
- Interventions
- tenofovir disoproxil and emtricitabine
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Newark, New Jersey + 1 more
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more